{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T22:44:57Z","timestamp":1789771497335,"version":"4.0.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T00:00:00Z","timestamp":1674691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>This review aimed to comprehensively analyze the safety and efficacy of erdafitinib in treating advanced and metastatic urothelial carcinoma and other solid tumors.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>PubMed, Embase, and ClinicalTrials.gov were searched until 10 February 2022. The safety outcome as adverse events and efficacy outcomes, including objective response rate, stable disease rates, and progressive disease rates, were selected and analyzed by comprehensive meta-analysis version 3.0 and STATA 15.0.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The most common all-grade adverse events were hyperphosphatemia, dry mouth, stomatitis, diarrhea, and dysgeusia. The occurrence of \u22653 adverse events was relatively low, and stomatitis and hyponatremia were the most common. Moreover, eye disorders could not be ignored. Efficacy in urothelial carcinoma patients was obviously better than in other solid tumor patients, with a higher objective response rate (0.38 versus 0.10) and lower progressive disease rate (0.26 versus 0.68). All responses occurred in patients with fibroblast growth factor receptor (FGFR) alteration. In those patients, a specific FGFR alteration (<jats:italic>FGFR3-TACC3<\/jats:italic>) was observed to have a maximum response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Erdafitinib has satisfactory clinical activity for metastatic urothelial carcinoma and other solid tumors, while the toxicity is acceptable. With more RCTs and combination therapy trials published, erdafitinib will be applied widely.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2022.907377","type":"journal-article","created":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T13:32:25Z","timestamp":1674739945000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":26,"title":["Safety and efficacy of the pan-FGFR inhibitor erdafitinib in advanced urothelial carcinoma and other solid tumors: A systematic review and meta-analysis"],"prefix":"10.3389","volume":"12","author":[{"given":"Xinyi","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyue","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghe","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhe","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelei","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,1,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2018.09.001","article-title":"Epidemiology of bladder cancer: A systematic review and contemporary update of risk factors in 2018","volume":"74","author":"Cumberbatch","year":"2018","journal-title":"Eur Urol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/jop.2017.024919","article-title":"Treatment of nonmetastatic muscle-invasive bladder cancer: American urological Association\/American society of clinical Oncology\/American society for radiation Oncology\/Society of urologic oncology clinical practice guideline summary","volume":"13","author":"Chang","year":"2017","journal-title":"J Oncol Pract"},{"key":"B4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2005.08.032","article-title":"Seven year update of an EORTC phase III trial of high-dose intensity m-VAC chemotherapy and G-CSF versus classic m-VAC in advanced urothelial tract tumours","volume":"42","author":"Sternberg","year":"2006","journal-title":"Eur J Cancer (Oxford Engl 1990)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"New Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-16-0589","article-title":"Discovery and pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor","volume":"16","author":"Perera","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2005.01.008","article-title":"Structural basis for fibroblast growth factor receptor activation","volume":"16","author":"Mohammadi","year":"2005","journal-title":"Cytokine Growth factor Rev"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.00840.x","article-title":"Regulation of growth factor signaling by FRS2 family docking\/scaffold adaptor proteins","volume":"99","author":"Gotoh","year":"2008","journal-title":"Cancer Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/s0092-8674(00)80252-4","article-title":"A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras\/MAPK signaling pathway","volume":"89","author":"Kouhara","year":"1997","journal-title":"Cell"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/nrm3528","article-title":"Exploring mechanisms of FGF signalling through the lens of structural biology","volume":"14","author":"Goetz","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104567","article-title":"The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder","volume":"151","author":"Roskoski","year":"2020","journal-title":"Pharmacol Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-14-3212","article-title":"The FGFR landscape in cancer: Analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res an Off J Am Assoc Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-14-0763","article-title":"FGFR-mediated reactivation of MAPK signaling attenuates antitumor effects of imatinib in gastrointestinal stromal tumors","volume":"5","author":"Li","year":"2015","journal-title":"Cancer Discovery"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-08-2816","article-title":"Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer","volume":"69","author":"Tomlinson","year":"2009","journal-title":"Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-S1-12","article-title":"Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer","author":"Baselga","year":"2011","journal-title":"Oncologist"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203726","article-title":"Fibroblast growth factor (FGF) signaling through PI 3-kinase and Akt\/PKB is required for embryoid body differentiation","volume":"19","author":"Chen","year":"2000","journal-title":"Oncogene"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ (Clinical Res ed.)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2018.01.012","article-title":"GRADE guidelines: 18. how ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence","volume":"111","author":"Sch\u00fcnemann","year":"2019","journal-title":"J Clin Epidemiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00660-4","article-title":"Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study","volume":"23","author":"Siefker-Radtke","year":"2022","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"New Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"17588359211015499","DOI":"10.1177\/17588359211015499","article-title":"Erdafitinib treatment in Brazilian patients with metastatic urothelial carcinoma (mUC): real-world evidence from an expanded access program 13","volume":"13","author":"Monteiro","year":"2021"},{"key":"B25","doi-asserted-by":"publisher","first-page":":4888-4897","DOI":"10.1158\/1078-0432.CCR-18-3334","article-title":"Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors","volume":"25","author":"Rastislav","year":"2019","journal-title":"%J Clin Cancer Res an Off J Am Assoc Cancer Res 25"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.7341","article-title":"Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors","volume":"33","author":"Tabernero","year":"2015","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"424-434","DOI":"10.1007\/s10637-017-0514-4","article-title":"Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors %J investigational new drugs","volume":"36","author":"Nishina","year":"2018"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.10482","article-title":"FGFR3-TACC3 fusion in solid tumors: mini review","volume":"7","author":"Costa","year":"2016","journal-title":"Oncotarget"},{"key":"B29","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s11523-019-00670-4","article-title":"First-in-Human phase I study of aprutumab ixadotin, a fibroblast growth factor receptor 2 antibody-drug conjugate (BAY 1187982) in patients with advanced cancer","volume":"14","author":"Kim","year":"2019","journal-title":"Target Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-19-0555","article-title":"First-in-Human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Cancer Discovery"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2017-CT106%JCancerResearch","article-title":"Abstract CT106: Ph I\/II study of FGF401 in adult pts with HCC or solid tumors characterized by FGFR4\/KLB expression","volume":"77","author":"Chan","year":"2017","journal-title":"Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1838484","article-title":"Clinical complexity of utilizing FGFR inhibitors in cancer therapeutics","volume":"29","author":"Chandana","year":"2020","journal-title":"Expert Opin Investigational Drugs"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2009.196","article-title":"The FGF23-klotho axis: endocrine regulation of phosphate homeostasis","volume":"5","author":"Razzaque","year":"2009","journal-title":"Nat Rev Endocrinol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2020.105587","article-title":"Fibroblast growth factor 23 counters vitamin d metabolism and action in human mesenchymal stem cells","volume":"199","author":"Meng","year":"2020","journal-title":"J Steroid Biochem Mol Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.478","article-title":"FGF receptors control vitamin d and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone","volume":"26","author":"Wohrle","year":"2011","journal-title":"J Bone Miner Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2003.12.102","article-title":"FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa","volume":"314","author":"Shimada","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00506.x","article-title":"Effect of fibroblast growth factor-23 on phosphate transport in proximal tubules","volume":"68","author":"Baum","year":"2005","journal-title":"Kidney Int"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201700006R","article-title":"Differential regulation of renal klotho and FGFR1 in normal and uremic rats","volume":"31","author":"Mu\u00f1oz-Casta\u00f1eda","year":"2017","journal-title":"FASEB J Off Publ Fed Am Societies Exp Biol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/17.20.5896","article-title":"Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain","volume":"17","author":"Mohammadi","year":"1998","journal-title":"EMBO J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2010.281","article-title":"FGF23 or PTH: which comes first in CKD","volume":"78","author":"Isakova","year":"2010","journal-title":"Kidney Int"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.2778","article-title":"Fibroblast growth factor receptor inhibitor-associated retinopathy","volume":"138","author":"Parikh","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1055\/a-1403-3068","article-title":"Drug-induced pseudo-central serous chorioretinopathy in carcinoma patients","volume":"238","author":"Jung","year":"2021","journal-title":"Klinische Monatsblatter fur Augenheilkunde"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.05.027","article-title":"Serous retinopathy associated with mitogen-activated protein kinase kinase inhibition (Binimetinib) for metastatic cutaneous and uveal melanoma","volume":"122","author":"van Dijk","year":"2015","journal-title":"Ophthalmology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2016.0090","article-title":"Subretinal fluid associated with MEK inhibitor use in the treatment of systemic cancer","volume":"134","author":"Weber","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2015.07.005","article-title":"Proliferative vitreoretinopathy: A new concept of disease pathogenesis and practical consequences","volume":"51","author":"Pastor","year":"2016","journal-title":"Prog retinal eye Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.tice.2021.101547","article-title":"Plumbagin inhibits proliferation, migration, and invasion of retinal pigment epithelial cells induced by FGF-2","volume":"72","author":"Zhang","year":"2021","journal-title":"Tissue Cell"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.09.028","article-title":"The fibroblast growth factor receptors, FGFR-1 and FGFR-2, mediate two independent signalling pathways in human retinal pigment epithelial cells","volume":"337","author":"Rosenthal","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1629","article-title":"Targeting FGFR3 alterations with adjuvant infigratinib in invasive urothelial carcinoma: the phase III PROOF 302 trial","volume":"18","author":"Pal","year":"2022","journal-title":"Future Oncol (London England)"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.907377\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,26]],"date-time":"2023-01-26T13:32:28Z","timestamp":1674739948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.907377\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,26]]},"references-count":48,"alternative-id":["10.3389\/fonc.2022.907377"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.907377","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,26]]},"article-number":"907377"}}